- Home
- FEMY vs IGC Comparison
FEMY vs IGC Comparison
Compare FEMY & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- IGC
- Stock Information
- Founded
- FEMY 2004
- IGC 2005
- Country
- FEMY United States
- IGC United States
- Employees
- FEMY N/A
- IGC N/A
- Industry
- FEMY Medical/Dental Instruments
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- IGC Health Care
- Exchange
- FEMY Nasdaq
- IGC Nasdaq
- Market Cap
- FEMY N/A
- IGC 18.0M
- IPO Year
- FEMY 2021
- IGC N/A
- Fundamental
- Price
- FEMY $1.23
- IGC $0.30
- Analyst Decision
- FEMY Strong Buy
- IGC Strong Buy
- Analyst Count
- FEMY 2
- IGC 2
- Target Price
- FEMY $11.50
- IGC $3.88
- AVG Volume (30 Days)
- FEMY 233.4K
- IGC 262.5K
- Earning Date
- FEMY 05-08-2025
- IGC 02-18-2025
- Dividend Yield
- FEMY N/A
- IGC N/A
- EPS Growth
- FEMY N/A
- IGC N/A
- EPS
- FEMY N/A
- IGC N/A
- Revenue
- FEMY $1,629,108.00
- IGC $1,236,000.00
- Revenue This Year
- FEMY $441.89
- IGC N/A
- Revenue Next Year
- FEMY $101.29
- IGC $18.34
- P/E Ratio
- FEMY N/A
- IGC N/A
- Revenue Growth
- FEMY 51.97
- IGC 1.65
- 52 Week Low
- FEMY $0.86
- IGC $0.25
- 52 Week High
- FEMY $1.80
- IGC $0.63
- Technical
- Relative Strength Index (RSI)
- FEMY 47.30
- IGC 53.06
- Support Level
- FEMY $1.07
- IGC $0.27
- Resistance Level
- FEMY $1.29
- IGC $0.30
- Average True Range (ATR)
- FEMY 0.09
- IGC 0.02
- MACD
- FEMY 0.02
- IGC 0.00
- Stochastic Oscillator
- FEMY 73.91
- IGC 69.74
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.